Kura Oncology’s Groundbreaking Findings: Tipifarnib and Alpelisib Combination Shows Promise in Treating Head and Neck Squamous Cell Carcinoma – A Preliminary Report from Phase 1/2 Clinical Trial
Kura Oncology Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpe… First demonstration that precision combination therapies can achieve a durable clinical response in PIK3CA-dependent HNSCC Preclinical data support potential to address ~45% of HNSCC tumors that harbor HRAS overexpression and/or PIK3CA mutation SAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE)…